Super Elongation Complex Disruptors for Cancer Therapeutics

Project: Research project

Description

Goal of the Project
Generate a data package that will support the advancement of a molecule derived from the current lead series of Super Elongation Complex Disruptors (SEC-KL) into an oncology clinical study by April 15, 2023, or a suitable alternate molecule or back-up (SEC-BU) by April 15, 2024 and/or the licensing of the intellectual property associated with this collaboration project to a third party by April 15, 2024.
Target Product Profile
The project aims to develop a medicinal therapy that will:
• Disrupt oncogenic transcriptional programming
• Reduce/eliminate tumor cell proliferation
• Improve survival outcome for patients
StatusActive
Effective start/end date4/15/194/14/24

Funding

  • Lakeside Discovery, LLC (Agmt 5/18/18)

Fingerprint

Intellectual Property
Licensure
Cell Proliferation
Survival
Neoplasms
Therapeutics
Clinical Studies
SEC Translocation Channels
Lead